EL7.AI
StocksMediumUpdated•Originally published 13 April 2026•Updated 14 April 2026•
1 min read

Analysts Project Massive Upside for Omeros and Assertio Amid Broad Earnings Revisions

Key Facts

1The average analyst price target for Encompass Health (EHC) indicates a potential upside of 31.7%.
2Analysts expect a 75.6% upside for Relmada Therapeutics (RLMD) based on the mean of price targets.
3Both companies show positive trends in earnings estimate revisions, which is a strong indicator of future performance.

Wall Street analysts have significantly expanded their bullish projections, with Omeros (OMER) now leading the group with a staggering potential upside of 266.7% based on average price targets. The positive sentiment extends to other biotech players, including Assertio (ASRT) and Nurix Therapeutics (NRIX), which are projected to rally by 115.1% and 85.8% respectively. This wave of optimism has also reached the technology and energy sectors, with Extreme Networks (EXTR) seeing a 32.4% upside target and SM Energy (SM) positioned for a 27.9% gain. These new projections build upon previous positive outlooks for Encompass Health and Relmada Therapeutics, all supported by a consistent trend of upward earnings per share (EPS) revisions. Analysts view these broad-based estimate hikes as a reliable indicator of strengthening financial health across multiple industries, positioning these stocks as key targets for growth-oriented investors.